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ABSTRACT
Background: Pegylated arginine deiminase (ADI-PEG 20) is a metabolism-based strategy that depletes 
arginine, resulting in tumoral stress and cytotoxicity. Preclinically, ADI-PEG 20 modulates T-cell activity and 
enhances the therapeutic efficacy of programmed death-1 (PD-1) inhibition.
Methods: A phase 1b study, including a dose-escalation cohort and an expansion cohort, was undertaken 
to explore the effects of ADI-PEG 20 in combination with pembrolizumab, an anti-PD-1 antibody, for 
safety, pharmacodynamics, and response. CD3 levels and programmed death-ligand 1 (PD-L1) expression 
were assessed in paired biopsies collected prior to and after ADI-PEG 20 treatment but before 
pembrolizumab.
Results: Twenty-five patients, nine in the dose-escalation cohort and sixteen in the expansion cohort, 
were recruited. Treatment was feasible with adverse events consistent with those known for each agent, 
except for Grade 3/4 neutropenia which was higher than expected, occurring in 10/25 (40%) patients. 
Mean arginine levels were suppressed for 1–3 weeks, but increased gradually. CD3+ T cells increased in 10/ 
12 (83.3%) subjects following ADI-PEG 20 treatment, including in three partial responders (p = .02). PD-L1 
expression was low and increased in 3/10 (30%) of subjects. Partial responses occurred in 6/25 (24%) 
heavily pretreated patients, in both argininosuccinate synthetase 1 proficient and deficient subjects.
Conclusions: The immunometabolic combination was safe with the caveat that the incidence of neu-
tropenia might be increased compared with either agent alone. ADI-PEG 20 treatment increased T cell 
infiltration in the low PD-L1 tumor microenvironment. The recommended phase 2 doses are 36 mg/m2 
weekly for ADI-PEG 20 and 200 mg every 3 weeks for pembrolizumab.
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Introduction
Arginine deprivation therapy with the amino acid degrading 
enzyme, pegylated arginine deiminase (ADI-PEG 20), has 
shown clinical efficacy in a variety of cancers.1–6 Moreover, 
ADI-PEG 20 potentiated chemotherapy with superior response 
rates and a side-effect profile mostly consistent with that 
expected for the chemotherapy alone in pancreatic cancer, 
non-small cell lung cancer, malignant pleural mesothelioma, 
and hepatocellular carcinoma.7–9 These promising response 
rates and good safety profiles of ADI-PEG 20-containing che-
motherapy have led to ongoing registration studies in multiple 
cancers.
Although ADI-PEG 20 has been combined with cytotoxic 
agents in the clinic, its role has remained unexplored with 
immunotherapy. Immune checkpoint therapy (ICT) has been 
approved for a variety of indications, and has revolutionized 
cancer treatment in recent years.10 Specifically, programmed 
death-1 (PD-1) inhibition is most effective in some tumor types 
enriched for programmed death-ligand 1 (PD-L1) 
expression.11 However, many tumors are low or deficient in 
tumor immunity, and thus, remain insensitive to ICT. 
A common strategy is to co-treat with an agent that would 
modulate tumor immunity, thereby increasing susceptibility to 
the PD-1/PD-L1 blockade.
Specifically, arginine and citrulline, the degradation product 
of ADI-PEG 20, are important regulators of immune 
responses.12 In terms of a tumor suppressive role, abundant 
extracellular arginine may promote regulatory T cell activity 
while effector T cell function is inhibited by tumoral arginase- 
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2.13 Moreover, laboratory studies with ADI-PEG 20 reveal 
complex immunomodulatory effects on T cells: decreasing 
regulatory T cells and inhibiting CTLA-4 and PD-1 expression 
on effector T cells.14 Furthermore, ADI-PEG 20 induced PD- 
L1 expression on cancer cells in vitro, a proinflammatory 
tumor immune microenvironment in vivo, and the combina-
tion with an anti-PD-1/PD-L1 antibody resulted in tumor 
shrinkage in arginine-auxotrophic murine tumor models com-
pared to either ADI-PEG 20 or the antibody alone.14–16 
Though the regulatory mechanism remains unclear, the fact 
that tumoral PD-L1 is modulated in a STAT3-dependent man-
ner by tetrahydrobiopterin (BH4), the nitric oxide synthase 
cofactor that converts arginine to nitric oxide, emphasizes the 
close relationship between arginine metabolism and 
immunity.17 These data supported the testing of ADI-PEG 
20, with its known immunomodulatory activity, in combina-
tion with ICT.
Here, we report on the safety and preliminary efficacy of the 
first clinical trial of ADI-PEG 20 combined with pembrolizu-
mab, and the effects on tumor immunity.
Methods
Objectives
From prior experience, ADI-PEG 20 exhibited acceptable 
safety profiles when administered at the recommended dose 
of 36 mg/m2 in combination with specific chemotherapy 
regimens.7–9 The safety of ADI-PEG 20, however, has not 
been documented with ICTs. Thus, we conducted an open- 
label, single-center, phase 1b trial of ADI-PEG 20 plus pem-
brolizumab with the primary objective to assess safety and 
tolerability of the combination (ClinicalTrials.gov: 
NCT03254732). The secondary objectives were to assess the 
maximum tolerated dose (MTD) for a recommended phase 2 
dose, progression-free survival (PFS), overall survival (OS), 
overall response rate (ORR) by RECIST 1.1 and by Immune- 
Related Response Criteria (irRC),18 and the effect of ADI-PEG 
20 on the expression of PD-L1 and T-cell infiltration.
Subjects
All subjects were recruited at National Cheng Kung University 
Hospital. Eligible subjects were over 18 years of age, with 
a confirmed advanced solid tumor that failed prior systemic 
therapy, measurable disease, archival tumor tissue, ECOG per-
formance status of 0 or 1, adequate hematologic, hepatic, and 
renal function and an expected survival of at least 3 months. 
No anti-cancer therapy could be received in the 2 weeks prior 
to study entry. Additionally, patients with uncontrolled inter-
current illness, expected noncompliance, history of another 
primary cancer unless unlikely to affect outcome, prior ADI- 
PEG 20 therapy, prior immunotherapy, and known allergy to 
ADI-PEG 20 were ineligible.
Study design
In the dose-escalation cohort, a “3 + 3 + 3” design was applied. 
The starting dose in cohort 1 was ADI-PEG 20 at 36 mg/m2 
weekly, which represented 100% of the typical dose, and 1 mg/ 
kg pembrolizumab every three weeks, which was 50% of the 
USA FDA approval dose for melanoma.19 The safety of ADI- 
PEG 20 at this dose has been demonstrated either as mono-
therapy or in combination with chemotherapy.1–9 The first 
subject received two drugs on the same day with a week of 
safety follow up before the next 2 subjects were to be enrolled. 
Dose-limiting toxicities (DLTs) were assessed during the first 
cycle. Without any DLT occurring, the enrollment would esca-
late into cohort 2, with pembrolizumab increased to 200 mg. In 
all cohorts, if 1/3 had reported a DLT, additional enrollment of 
3 patients was required for up to two times. If the DLT rate 
occurred in 2/3, 3/6, 3/9, or more, the cohort would meet the 
maximum administered dose and require de-escalation for 
MTD search.
After dose determination, up to 20 subjects could be 
enrolled into an expansion MTD cohort with the addi-
tional criteria of pre-treatment tissue confirming low PD- 
L1, defined as ≤49% expression by immunohistochemical 
(IHC) staining (Dako 22C3 pharmDx). The subjects first 
received ADI-PEG 20 monotherapy on days 1, 8 and 15. 
The subjects underwent re-biopsy 24–28 h after the 3rd 
dose of ADI-PEG 20, followed by administration of pem-
brolizumab. Subjects then continued on the scheduled 
regimen. Baseline tomography images for tumor assess-
ment were conducted, and then every 9 weeks while on 
treatment. Subjects received the combination regimen for 
up to 24 weeks if the tumor showed stable disease (SD) or 
better, then ADI-PEG 20 monotherapy after 24 weeks. 
RECIST 1.1 was used for determining progressive disease 
(PD) and study drug discontinuation. Subjects with PD 
might remain on study upon investigators’ decision and if 
PD was not confirmed in 4 to 6 weeks with repeat 
imaging.
Safety
All subjects were evaluated for safety by routine physical exam-
ination, and adverse event (AE) assessment by the NCI- 
CTCAE version 4.03. Complete blood counts and serum chem-
istry were obtained at screening and every third week. 
Endocrine data related to immune-related AEs were obtained 
at baseline and at weeks 11 and 23. Monitoring continued for 
30 days after the treatment and until AE stabilization or 
resolution.
DLTs were defined as severe AEs that could be attributed to 
the study treatment during the first 21 days. These events 
included prolonged grade 4 neutropenia, febrile neutropenia 
with temperature up to 38.5°C or higher, grade 3–4 anemia or 
grade 4 thrombocytopenia that required transfusion therapy, 
grade 3–4 nonhematologic toxicity with the exception of alo-
pecia, controllable gastrointestinal symptoms, rash, and fati-
gue, or any other asymptomatic laboratory evaluation unless 
clinically significant. In addition, grade 2 immune-related toxi-
city and any resultant DLT would be monitored. If a subject 
did not receive the qualifying doses for assessment due to 
reasons other than toxicity, they would be non-evaluable and 
replaced.
e1943253-2 K.-Y. CHANG ET AL.
Pharmacodynamic and immunogenicity evaluations
Blood samples were taken before each dose of ADI-PEG 20 for 
weeks 1–3, and then every other week from weeks 5–23 to 
analyze arginine and citrulline levels and for immunogenicity 
analyses. An arginine level below 10 μM post ADI-PEG 20 
dosing was defined as arginine suppression.9
Immunohistochemical staining
Argininosuccinate synthetase 1 (ASS1) staining and reporting 
followed the previous protocol.5,20 Immune phenotyping was 
performed for CD3 (Cat#A0452, Dako/Agilent, Santa Clara, 
CA, USA) and PD-L1 (Cat#13684S, Cell Signaling, Danvers, 
MA, USA), staining were conducted as described previously.21
Statistical consideration
Categorical variables were summarized with frequency and 
percentage. The survival data were summarized with median 
and 95% confidence interval (CI). Continuous variables were 
summarized with mean and median. Two-tailed paired t tests 
were used for data analysis with a significance level of 0.05, and 
were calculated by Prism 7 (GraphPad Software, San Diego, 
CA, USA).
Results
Patient enrollment and drug administration
Patient enrollment was between July 2017 and 
August 2018, and the data cut off was 11 July 2019. The 
subjects were heavily pretreated for various malignancies 
with a median of 3 prior lines of chemotherapy (ranging 
from 1 to 6; Table 1). Nine subjects were enrolled in the 
dose-escalation portion, including six in cohort 1 and 
three in cohort 2, and all subjects were evaluable. There 
was one subject only in cohort 1 reported for DLT. From 
cohort 2, we defined the MTD to be 36 mg/m2 ADI-PEG 
20 and 200 mg of pembrolizumab, and enrolled an addi-
tional sixteen patients in an expanded MTD cohort 
(Figure 1). The mean/median number of treatments was 
15/12 and 5/4, respectively, for ADI-PEG 20 and 
pembrolizumab.
Toxicities
Of the non-hematological AEs reported, most were mild 
(Table 2). Fatigue occurred in 12/25 (48%) subjects, and 
was all grades 1–2. Pyrexia occurred in 7/25 (28%) subjects, 
with two reported as grade 3. Other AEs, such as arthralgia 
and pruritus, were less frequent. For grades 3–4 AEs, 14 
episodes of neutropenia occurred in 10/25 (40%) subjects 
(Table 3). Among them, eight received colony stimulating 
factors, but only one required longer support up to 5 days. 
Three subjects had febrile neutropenia requiring a week of 
antibiotics and colony stimulating factor support. Six sub-
jects required drug interruption according to the treatment 
schedule. Notably, pembrolizumab was discontinued in 
subject D004 due to concurrent development of grade 3 
hepatitis, which was regarded a DLT that required corti-
costeroid management.
Table 1. Patient characteristics.
Cohort 1 Cohort 2 MTD Cohort Total
n = 6 n = 3 n = 16 n = 25
Age – median (range) 54 (29–72)
Sex – Male, Female 3,3 3,0 15,1 21, 4
Cancer
Head and neck 2 - - 1
Thymic 1 - - 1
Gastric 2 - - 2
Nasopharyngeal carcinoma 1 - 1 2
Esophageal - 2 5 7
Cutaneous melanoma - 1 - 1
Mucosal melanoma - - 1 1
Colorectal cancer - - 2 2
Cholangiocarcinoma - - 3 3
Salivary gland - - 1 1
Hepatocellular carcinoma - - 1 1
Pancreatic - - 1 1
Cervical - - 1 1
Metastatic sites
Lymph nodes 2 2 13
Liver 2 2 4
Lung - 2 9
Others# 3* - 3**
Prior lines of chemotherapy
1 1 - 2 3
2 1 1 5 7
3 3 1 3 7
4 1 1 4 6
5 - - 1 1
6 - - 1 1
Prior radiotherapy 5 2 10 17
Footnotes: #Others include: *pleura (1), bone (1), spleen (1); **gluteal (2), pleural seeding (1)
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Responses
Regarding the ORR, 6 of 25 (24%) enrolled and 6 of 23 (26.1%) 
per protocol evaluable subjects had a partial response (PR): 2 in 
the dose-escalation cohort 1; and 4 in the MTD cohort (Table 
4). By irRC, the same 6 subjects had a PR (Figure 2 & 
Supplementary Table S1). SD was observed as the best response 
of tumor measurement in 7/25 (28%) enrolled and 7/23 
(30.4%) per protocol evaluable subjects. Together, the overall 
disease control rate was 13/25 (52%) enrolled and 13/23 
(56.5%) per protocol evaluable subjects. Notably, two subjects 
had initial PD followed by SD (Figure 3), which was sustained 
until the sixth month before PD in one subject (B008), while 
the other subject withdrew in the fourth month due to a new 
bone metastasis (B022).
Thirteen subjects were reported for mortality during the 
post-treatment follow up. The median OS was 8.5 months 
Figure 1. Flow of the clinical trial.
Table 2. Summary of adverse events.
Cohort 1 2 MTD
Grade 1/2 3 4 1/2 3 4 1/2 3 4
Blood disorder
Anaemia - - - - - - 2 - -
Thrombocytopenia 2 - - 2 - - 3 1 -
Leukopenia 4 4 - 2 1 - 2 1 1
Neutropenia - 4 4 - 1 2 - 2 1
Lymphocytopenia - - - 1 2 - - - -
Lab disorder
Increased Alk-P 1 - - - - - - 1 -
Increased ALT - 1 - - - - 2 - -
Increased AST - 1 - 1 - - 2 - -
Decreased ACTH - - - - - - 1 - -
Decreased cortisol 1 - - - - - - - -
Increased TSH 1 - - - - - - - -
Decreased free T4 1 - - - - - - - -
General disorder
Appetite decreased - - - - - - 2 - -
Arthralgia - - - - - - 4 1 -
Aspiration - - - - - - - 1 -
Fatigue 2 - - 2 - - 8 - -
Febrile neutropenia - - - - 2 - - 1 -
Laryngitis - - - - - - - 1 -
Pruritus - - - - - - 1 2 -
Pyrexia - - - 1 - - 4 2 -
Rash 2 - - 1 - - 2 - -
Urticaria - - - - - - 1 2 -
NOTE. Toxicities listed are those possibly, probably or definitely related to treatment (one or both study drugs). Data are presented as the number of events per dose 
and grade according to NCI-CTCAE version 4.03. No related grade 5 toxicities were reported. Single events of grade 1/2 blood or general disorders are not listed in the 
table.
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(95% CI, 6.6~ not reached) for all subjects with 10/23 censored, 
and 7.8 months (95% CI, 2.5~ not reached) for the MTD 
cohort with 6/14 censored. The median PFS was 1.9 months 
(95% CI, 1.9 ~ 6) by RECIST and 3.9 months (95% CI, 
1.9 ~ 6.7) by irRC for all subjects, and 2.9 (95% CI, 1.9 ~ 7.2) 
by irRC for the MTD cohort.
Pharmacodynamics and immunogenicity
Mean arginine levels were undetectable for weeks 1–3, and 
remained suppressed to ~50% for the 6 months of testing 
(Figure 4). In contrast, citrulline levels peaked early on, and 
did not return to baseline levels. There was a gradual increase 
in levels of anti-ADI-PEG 20 antibodies, reaching a plateau by 
Table 3. List of all neutropenia events.
Case Week Grade Action for ADI-PEG 20 Action for Pembrolizumab Growth factors support (days) Antibiotic (days) Fever
D004 3 4 Interrupted Withdrew* 3 - -
14 3 Interrupted N/A - - -
19 4 Interrupted N/A 1 - -
22 3 Interrupted N/A - - -
26 3 Interrupted N/A - - -
D006 3 4 - - 2 - -
D007 3 4 Interrupted Interrupted - - -
D009 3 3 - - - - -
D012 3 3 - - 3 - -
D013 4 4 Interrupted Interrupted 2 7 +**
D014 3 4 Interrupted Interrupted 1 7 +**
B001 2 3 - - 1 - -
B015 5 3 Interrupted Interrupted 1 - -
B022 3 4 Interrupted - 5 8 +**
*Pembrolizumab withdrew because of DLT (Grade 3 hepatitis). 
**The events were also graded as Grade 3 febrile neutropenia.
Table 4. Summary of responses and survival.
Enrolled Evaluable* PR SD Response rate* Disease-control rate*
Cohort 1 6 6 2 2 33.3% 66.7%
Cohort 2 3 3 0 2 0 66.7%
MTD Cohort 16 14 4 3** 28.6% 50%
All 25 23 6 7 26.1% 56.5%
* Efficacy analysis is based on Per-Protocol Evaluable Population: patients treated with ≥ 2 doses of ADI-PEG 20 and 1 dose of pembrolizumab during the first 4 weeks, 
and have ≥1 post-treatment scan. 
**Two had PD in initial evaluation but turned SD with repeated follow-up imaging.
Figure 2. The swimmer plot shows the treatment response (RECIST 1.1) for subjects, noted with immune-related response criteria (irRC) listed aside. the plot is sorted by 
cohort and time on treatment. Note the subject B029 was a censored event as he was lost to follow up.
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week 17. For 5 of 6 subjects with a PR (D008, B007, B015, B020, 
B035), the duration of arginine suppression was only 3– 
4 weeks, with a concomitant rise in antibody levels 
(Supplementary Figure S1). Nevertheless, the responses per-
sisted, ranging from 6 to 37 weeks (Figure 3). In the sixth 
subject with PR (D004), arginine depletion was prolonged for 
3–4 months and the response persisted for 10 weeks. Two other 
subjects with SD, B008 and D012, also exhibited prolonged 
arginine depletion (data not shown).
The median ASS1 staining at the baseline was 65% positive 
and the mean was 54%. PRs were observed in subjects with 
varying degrees of ASS1 expression (>95, 0, <5, 70, 40 and 
40%), with no clear correlation. This was similarly noted in SD 
subjects (Supplementary Table S1). In the 14 available matched 
samples, ASS1 expression was variably altered after ADI-PEG 
20 injection (P > .05, Figure 5).
Increased CD3+ cells infiltration (paired tumor biopsies)
Twelve-paired samples were available to evaluate CD3+ T cells. 
The percentage of CD3+ T cells increased post-ADI-PEG 20 
treatment in the 3 responders with assessable tumor tissue 
(B007, B015, and B035). In the non-responders, the percentage 
of CD3 + T cells increased in 7 subjects post-ADI-PEG 20 
treatment (Figure 5, Supplementary Table S1). Overall, ADI- 
PEG 20 treatment increased CD3+ T cell levels in 10/12 (83.3%, 
P = .02) patients.
PD-L1 levels at baseline were evaluated for 6 subjects from 
the dose-escalation cohort, which was absent (0-<1%) in 4 and 
low (1-<50%) in 2. Among them, only one PR was observed in 
the subject with the highest expression at 25% (D004). Paired 
tumor tissue samples were evaluated for PD-L1 expression in 
10 subjects from the MTD cohort; PD-L1 expression increased 
in 3 subjects (30%, Figure 5).
Figure 3. The spider plot shows measurement of target lesion of each subjects over time. all the measurements followed RECIST 1.1 criteria.
Figure 4. Pharmacodynamics and immunogenicity related to experimental drugs was measured. the level of arginine/citrulline level (left panel) and the anti-ADI-PEG 20 
antibody titer (right panel) by time is summarized in dot-line plots. each dot represents mean levels of 25 patients with 25% and 75% percentiles (±SEM).
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Discussion
This is the first clinical report on the safety and tolerability of 
ADI-PEG 20 combined with ICT. Arginine depletion with 
ADI-PEG 20 and pembrolizumab was safe, and increased 
tumoral CD3+ T cells in the heavily pretreated subjects. Such 
T cell infiltration has been shown to correlate with responses, 
especially with ICT.22 The immune effect was supported by 
possible pseudoprogression in two cases with initial PD to SD 
by irRC (Figure 3).18
The combination was well tolerated. Notably, among the 
thirteen fatalities, including the five subjects that died within 
three months (B006, B009, B010, B014, and D014; Figure 2), all 
were tumor-related and none were linked to drug AEs. 
Concerning grade 3–4 AEs, neutropenia occurred in 40% 
(n = 10/25), including the 3 subjects experiencing grade 3 
febrile neutropenia. These side effects are uncommon with 
immune checkpoint inhibitors, as noted in the package insert 
for pembrolizumab.23,24 Similarly, hematologic AEs are infre-
quently observed with ADI-PEG 20 monotherapy, but are 
more common when combined with chemotherapy.5,8,9 Thus, 
based on our phase 1b study, we observed an increase in 
neutropenic AEs when ADI-PEG20 was combined with pem-
brolizumab. Interestingly, the neutropenia was more evident in 
the dose escalation cohort subjects, where both drugs were 
combined at the beginning, compared to the MTD subjects, 
where the first pembrolizumab injection was staggered 16 days 
after the first dose of ADI-PEG 20 (Table 2). Moreover, most 
events occurred in the first 5 weeks during peak arginine 
depletion. In subject D004 with multiple episodes of neutrope-
nia, prolonged depletion of arginine was also noted. Notably, 
while arginine deprivation appears not to impact neutrophil 
activation as measured by chemotaxis, phagocytosis and gen-
eration of ROS, both increased apoptosis and cytokine dysre-
gulation may account for the higher rates of neutropenia in the 
context of arginine suppression and PD1 blockade.16,25–27 
Nonetheless, the precise mechanism for these synergistic AEs 
remains unknown, but should be anticipated and studied 
further in future combination trials.
Consistent with previous studies, arginine levels decreased 
promptly with a corresponding increase in citrulline levels 
(Figure 4).5,28 The arginine depletion was maintained for 
2 months compared to at least 4 months in clinical trials of 
ADI-PEG 20 with chemotherapy.7–9 However, as the trough 
levels were sustained for several weeks before peaking of the 
drug antibody titer, this provides a window of opportunity for 
T cell infiltration and response to ICT.29 As noted in multiple 
prior ADI-PEG 20 studies, although blood arginine levels 
increase with the appearance of anti-ADI-PEG 20 antibodies, 
the blood draws were performed weekly immediately before 
ADI-PEG 20 dosing, therefore reflecting static rather than 
dynamic changes in amino acid levels. Moreover, the concen-
tration of arginine and its metabolites within the cancer micro-
environment following ADI-PEG 20 therapy remains unclear 
and requires further study. Nevertheless, our data translate the 
earlier preclinical data that arginine modulation impacts both 
PD-L1 expression and T cells distribution,14 and validate 
observations of altered T cell localization in a recent ADI- 
PEG 20 triplet chemotherapy study in patients with 
mesothelioma.16
Objective responses were observed in subjects with thymic 
cancer, nasopharyngeal carcinoma, cholangiocarcinoma, 
mucosal melanoma, esophageal cancer, and cervical cancer, 
with the latter three cancer types designated by the FDA for 
treatment with pembrolizumab. These patients did not receive 
prior ICTs because the reimbursement program by the Taiwan 
Health Insurance Administration initiated from mid-2019. 
Although the objective responses may be attributed to pem-
brolizumab alone, with response rates ranging from 8 to 30% in 
published studies, a contributory role of ADI-PEG 20 cannot 
be excluded.30–35 Arguably, responses were not correlated with 
Figure 5. The paired immunohistochemistry results in tissue at screening and at week 3 biopsy are quantified in the dot-line plots (left panels). the subjects with 
response were labeled in red color. note that in CD3, there are four (33.3%) increase by >10%. representative CD3 and PD-L1 IHC images are from subject B015, a partial 
responder (right panels).
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the degree of ASS1 expression, however our study was small 
overall and included subjects with a wide variety of cancers. 
Though patient selection with ASS1 deficiency resulted in 
significantly improved outcome for ADI-PEG 20 in 
mesothelioma,5 ASS1-independent responses have been 
described when combined with chemotherapy.8,9 This suggests 
the capacity of tumor cells to replete arginine may be compro-
mised or insufficient to maintain cell viability in the context of 
multimodality chemotherapy. Alternatively, although 
expressed by the tumor, ASS1 may be nonfunctional.36 
Nonetheless, it appears that ADI-PEG 20 has multiple anti- 
tumor mechanisms, by acting directly on certain tumors that 
are arginine deficient as well as indirectly via an immune effect.
PD-L1 was increased in 3 of 10 paired tumoral samples, 
including 1 of the 2 subjects with a PR. Specific chemotherapies 
have been documented to upregulate PD-L1 expression in 
various preclinical models and also to synergize with ICT.37 
In a head and neck cancer study, cisplatin modulated tumoral 
PD-L1 expression, notably converting 9/13 subjects from nega-
tive to positive PD-L1 status, providing a rationale for the ICT 
combination.38,39 Further studies of the mechanisms under-
lying PD-L1 induction by ADI-PEG 20 are needed in specific 
tumor types.
Since arginine depletion is known to impact T cell anti-tumor 
activity as well as the viability of urea cycle deficient tumor cells, 
the benefits of ADI-PEG 20 in the context of tumor immunity 
have been questioned. Specifically, L-arginine has crucial roles in 
anti-tumor T cell proliferation, differentiation, and survival.40 
For instance, in a phase II clinical trial of azacitidine and vorino-
stat in patients with acute myeloid leukemia (AML), cancer 
antigens failed to enhance anti-tumor immunity because of 
exhausted T cells in a low arginine environment generated by 
AML blast arginase activity.41 In our study, the increased T cells 
in the sequential tumor biopsies indicate that ADI-PEG 20 has 
less impact on T cell anti-tumor activity. Indeed, it has been 
shown that T cells recycle the citrulline by-product of ADI-PEG 
20 via an amino acid transporter to regenerate endogenous 
arginine.42 Moreover, recent work by Lee and colleagues identi-
fied urea cycle dysregulation in tumors, including ASS1 defi-
ciency, as enhancing tumorigenicity but importantly also 
increasing susceptibility to ICT.43 This was attributed to higher 
presentation of neoantigens, due to accumulation of pyrimidine- 
rich transversion mutational bias that was a stronger predictor of 
ICT than tumor mutational burden. Collectively, given the 
increased tumoral PD-L1 expression with ADI-PEG 20 therapy, 
the combination with pembrolizumab seeks to bypass T cell 
exhaustion and supports further clinical studies of this novel 
immunometabolic strategy. Nevertheless, although all three 
responders with assessable tissue displayed a variably increased 
number of CD3+ T cells, it remains unanswered if the altered 
immunity was associated with the response. Given that tumor 
infiltrating lymphocytes are often related to prognosis and ICT 
treatment,44 our results are limited by the small sample size in 
this study, and larger trials are needed to more fully these aspects.
In conclusion, the combination of ADI-PEG 20 and pem-
brolizumab in heavily pretreated subjects was feasible. 
Objective responses were observed, but also with an apparent 
higher incidence of neutropenia that was manageable. The 
translational biopsies confirmed an immunomodulatory effect 
of ADI-PEG 20, with statistically significant T cell infiltration 
and evidence for PD-L1 induction. These conclusions, how-
ever, are based on a small and heterogeneous group of subjects, 
and further clinical trials are planned in patients enriched for 
defined arginine auxotrophic cancers.
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